Peptide Formulation Excipients

Excipient selection is critical for peptide formulation stability, safety, and efficacy. This reference compiles compatibility data for common excipients used in therapeutic peptide formulations, including stability enhancement, toxicity profiles, and formulation recommendations.

Excipient Classification

Category	Function	Examples	Typical Concentration
Buffer	pH control	Acetate, phosphate, citrate	10–50 mM
Tonicity agent	Osmolality adjustment	NaCl, sorbitol, mannitol	150–300 mOsm/kg
Stabilizer	Prevent degradation	Sucrose, trehalose, polysorbate	1–10% w/v
Preservative	Antimicrobial	Metacresol, phenol, benzyl alcohol	0.1–0.5% w/v
Antioxidant	Prevent oxidation	BHT, ascorbic acid, Met	0.01–0.1% w/v
Surfactant	Prevent aggregation	PS-80, PS-20, poloxamer	0.01–0.1% w/v
Co-solvent	Enhance solubility	Ethylene glycol, PEG	1–20% v/v
Chelator	Metal ion sequestration	EDTA, DTPA	0.01–0.1% w/v

Buffer Compatibility

Buffer	pH Range	Compatibility	Notes
Acetate	3.5–5.5	Excellent	Preferred for acidic formulations
Phosphate	5.8–8.0	Good	Avoid with Ca²⁺/Mg²⁺ (precipitation)
Citrate	3.0–6.0	Excellent	Chelates metals; good for oxidation-prone peptides
Histidine	5.5–6.5	Excellent	Good for protein formulations
Tris	7.0–9.0	Good	Temperature-dependent pH shift
Glycine	3.0–5.0, 8.5–10.5	Good	Good buffer capacity at extremes
Succinate	3.0–6.0	Excellent	Biocompatible; good stability

Buffer Concentration Guidelines

Concentration	pH Control	Osmolality Contribution	Application
5–10 mM	Minimal	<20 mOsm/kg	Low buffer requirement
10–25 mM	Moderate	20–50 mOsm/kg	Most formulations
25–50 mM	Strong	50–100 mOsm/kg	High buffer requirement
50–100 mM	Very strong	100–200 mOsm/kg	Specialized formulations

Tonicity Agent Compatibility

Agent	Osmolality (300 mOsm/kg)	Compatibility	Notes
NaCl	154 mM	Excellent	Standard isotonic agent
Sorbitol	5.4% w/v	Excellent	Non-ionic; good for proteins
Mannitol	5.5% w/v	Excellent	Lyophilization bulking agent
Glycerol	2.2% w/v	Good	May increase viscosity
Sucrose	10% w/v	Good	Lyophilization stabilizer
Trehalose	10% w/v	Excellent	Superior stability to sucrose
PEG 300	15–20% v/v	Good	Co-solvent and tonicity agent

Stabilizer Compatibility

Stabilizer	Mechanism	Compatibility	Concentration
Sucrose	Glassy state formation	Excellent	5–20% w/v
Trehalose	Glassy state formation	Excellent	5–20% w/v
Mannitol	Bulking agent	Excellent	5–20% w/v
Polysorbate 80	Surfactant (anti-aggregation)	Good	0.01–0.1% w/v
Polysorbate 20	Surfactant (anti-aggregation)	Good	0.01–0.1% w/v
BSA	Protein stabilizer	Variable	0.1–1% w/v
PEG 4000	Cryoprotectant	Good	1–5% w/v
Dextran	Bulking agent	Good	1–5% w/v

Sugar Stabilizer Comparison

Property	Sucrose	Trehalose	Mannitol	Sorbitol
Glass transition temperature (Tg)	65°C	115°C	15°C	-3°C
Hygroscopicity	Low	Very low	Low	Moderate
Reducing sugar	Yes	No	No	No
Maillard reaction risk	Yes	No	No	No
Protein stability	Good	Excellent	Good	Moderate
Cost	Low	Moderate	Low	Low

Preservative Compatibility

Preservative	Mechanism	Compatibility	Concentration
Metacresol	Protein denaturation	Good	0.15–0.3% w/v
Phenol	Protein denaturation	Good	0.2–0.5% w/v
Benzyl alcohol	Membrane disruption	Moderate	0.9–1.5% v/v
Chlorobutanol	Membrane disruption	Good	0.5% w/v
Thimerosal	Mercury-based	Variable	0.005–0.01% w/v
Phenol (m-cresol)	Protein denaturation	Good	0.15–0.3% w/v

Preservative Efficacy Testing

Test	Organism	Acceptance Criteria
USP <51>	A. brasiliensis, P. aeruginosa, S. aureus, E. coli	No increase at 14 days
Ph. Eur. 5.1.3	Same as USP	No increase at 14 days
In-use test	User-relevant organisms	No growth at 28 days

Antioxidant Compatibility

Antioxidant	Mechanism	Compatibility	Concentration
Methionine	Free radical scavenger	Excellent	0.01–0.1% w/v
Ascorbic acid	Reducing agent	Good	0.01–0.1% w/v
BHT	Lipid peroxidation inhibitor	Good	0.01–0.1% w/v
BHA	Lipid peroxidation inhibitor	Good	0.01–0.1% w/v
Sodium metabisulfite	Oxygen scavenger	Moderate	0.01–0.1% w/v
EDTA	Metal chelation	Excellent	0.01–0.1% w/v

Surfactant Compatibility

Surfactant	Type	HLB	Compatibility	Application
Polysorbate 80	Non-ionic	15	Excellent	Protein formulations
Polysorbate 20	Non-ionic	16.7	Excellent	Protein formulations
Poloxamer 188	Non-ionic	29	Excellent	IV formulations
Poloxamer 407	Non-ionic	22	Good	Controlled release
Brij 35	Non-ionic	16.9	Good	Solubilization
SDS	Anionic	40	Poor	Avoid (denatures)
CTAB	Cationic	N/A	Poor	Avoid (toxic)

Peptide-Specific Formulation Recommendations

Insulin Formulations

Excipient	Purpose	Concentration	Compatibility
Zinc	Hexamer stabilization	0.3–0.6 mg/mL	Excellent
Metacresol	Preservative	0.15–0.3%	Excellent
Phenol	Preservative	0.25–0.5%	Excellent
NaCl	Tonicity	0.3–0.8%	Good
Protamine	NPH formulation	Variable	Excellent

GLP-1 RA Formulations

Excipient	Purpose	Concentration	Compatibility
NaCl	Tonicity	0.41–0.75%	Excellent
Propylene glycol	Co-solvent	10–20%	Good
Phenol	Preservative	0.55%	Good
Polysorbate 20	Surfactant	0.01–0.02%	Good
Disodium phosphate	Buffer	3.2–5.2 mM	Excellent

Antimicrobial Peptide Formulations

Excipient	Purpose	Concentration	Compatibility
Acetate buffer	pH control	10–50 mM	Excellent
NaCl	Tonicity	0.9%	Good
EDTA	Metal chelation	0.01–0.1%	Good
Polysorbate 80	Anti-aggregation	0.01–0.1%	Good
PEG 400	Co-solvent	5–10%	Moderate

Excipient Toxicity Limits

Excipient	ADI (mg/kg/day)	Maximum Concentration	Toxicity
NaCl	No limit	0.9% (IV)	Hypernatremia at high doses
Sucrose	No limit	10% w/v	Osmotic diarrhea
Trehalose	No limit	15% w/v	Minimal
Polysorbate 80	25	0.1% w/v	Hypersensitivity (rare)
Metacresol	0.5–1.0	0.3% w/v	Local irritation
Phenol	0.1–0.5	0.5% w/v	Hepatotoxicity at high doses
Benzyl alcohol	5–20	1.5% v/v	Gasping syndrome (neonates)
EDTA	1.5–2.5	0.1% w/v	Calcium depletion
Propylene glycol	25–50	20% v/v	CNS depression at high doses

Formulation Development Workflow

1. Peptide characterization: pI, solubility, stability, aggregation propensity
2. Buffer selection: Based on peptide pI and stability pH profile
3. Tonicity adjustment: Target 280–320 mOsm/kg
4. Stabilizer screening: Sugars, surfactants, antioxidants
5. Preservative testing: If multi-dose formulation
6. Compatibility testing: Accelerated stability (40°C/75% RH, 2 weeks)
7. Optimization: Design of experiments (DoE)
8. Final formulation: Freeze-thaw, agitation, light stability

References

1. Wang YJ, et al. “Excipient effects on peptide stability.” J Pharm Sci 2007;96:1251-1265.
2. Kishore R, et al. “Excipient compatibility with therapeutic proteins.” BioDrugs 2012;26:221-232.
3. Chou DK, et al. “Excipient effects on peptide formulation stability.” AAPS PharmSciTech 2017;18:2481-2494.
4. Mensink MA, et al. “Excipients for peptide formulations.” Int J Pharm 2019;569:118547.
5. Jorgensen L, et al. “Peptide formulation excipients: a comprehensive review.” Adv Drug Deliv Rev 2022;185:114278.